{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:23:22Z","timestamp":1793910202225,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010666","name":"H2020 Research Infrastructures","doi-asserted-by":"publisher","award":["871029"],"award-info":[{"award-number":["871029"]}],"id":[{"id":"10.13039\/100010666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["REACTing"],"award-info":[{"award-number":["REACTing"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2\u2009&lt;\u2009EC50\u2009\u2264\u200920\u00a0\u00b5M. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection.<\/jats:p>","DOI":"10.1038\/s41598-020-70143-6","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T06:03:35Z","timestamp":1596521015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":302,"title":["In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication"],"prefix":"10.1038","volume":"10","author":[{"given":"Franck","family":"Touret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Nougair\u00e8de","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-8584","authenticated-orcid":false,"given":"Jacques","family":"van Helden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Decroly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Coutard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"70143_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523\u2013534 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"70143_CR2","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199\u20131207 (2020).","journal-title":"N. Engl. J. Med."},{"key":"70143_CR3","doi-asserted-by":"crossref","unstructured":"Callaway, E., Cyranoski, D., Mallapaty, S., Stoye, E. & Tollefson, J. The coronavirus pandemic in five powerful charts. Nature (2020).","DOI":"10.1038\/d41586-020-00758-2"},{"key":"70143_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"G Li","year":"2020","unstructured":"Li, G. & De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149\u2013150 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70143_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.coph.2019.07.006","volume":"48","author":"Y-S Cheng","year":"2019","unstructured":"Cheng, Y.-S., Williamson, P. R. & Zheng, W. Improving therapy of severe infections through drug repurposing of synergistic combinations. Curr. Opin. Pharmacol. 48, 92\u201398 (2019).","journal-title":"Curr. Opin. Pharmacol."},{"key":"70143_CR6","doi-asserted-by":"publisher","first-page":"104781","DOI":"10.1016\/j.antiviral.2020.104781","volume":"178","author":"R Manganaro","year":"2020","unstructured":"Manganaro, R. et al. Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors. Antiviral Res. 178, 104781 (2020).","journal-title":"Antiviral Res."},{"key":"70143_CR7","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"AH de Wilde","year":"2014","unstructured":"de Wilde, A. H. et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875\u20134884 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"70143_CR8","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1128\/AAC.03036-14","volume":"58","author":"J Dyall","year":"2014","unstructured":"Dyall, J. et al. Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885\u20134893 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"70143_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","volume":"26","author":"B Mercorelli","year":"2018","unstructured":"Mercorelli, B., Pal\u00f9, G. & Loregian, A. Drug repurposing for viral infectious diseases: how far are we?. Trends Microbiol. 26, 865\u2013876 (2018).","journal-title":"Trends Microbiol."},{"key":"70143_CR10","doi-asserted-by":"publisher","first-page":"31819","DOI":"10.1038\/srep31819","volume":"6","author":"L Delang","year":"2016","unstructured":"Delang, L. et al. The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. Sci. Rep. 6, 31819 (2016).","journal-title":"Sci. Rep."},{"key":"70143_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2019.05.005","volume":"168","author":"F Touret","year":"2019","unstructured":"Touret, F. et al. Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery. Antiviral Res. 168, 109\u2013113 (2019).","journal-title":"Antiviral Res."},{"key":"70143_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","volume":"107","author":"J Blaising","year":"2014","unstructured":"Blaising, J., Polyak, S. J. & P\u00e9cheur, E.-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 107, 84\u201394 (2014).","journal-title":"Antiviral Res."},{"key":"70143_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6, 16 (2020).","journal-title":"Cell Discov."},{"key":"70143_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cr.1990.1","volume":"1","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 1, 1\u20133 (2020).","journal-title":"Cell Res."},{"key":"70143_CR15","doi-asserted-by":"crossref","unstructured":"Yao, X. et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. (2020).","DOI":"10.1093\/cid\/ciaa237"},{"key":"70143_CR16","unstructured":"Hydroxychloroquine to Prevent Covid19 Pneumonia (ALBERTA HOPE-Covid19). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04329611 (2020)."},{"key":"70143_CR17","unstructured":"Efficacy and safety of darunavir and cobicistat for treatment of pneumonia caused by 2019-nCoV. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT042522745 (2020)."},{"key":"70143_CR18","unstructured":"Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04329832 (2020)."},{"key":"70143_CR19","unstructured":"Lack of Antiviral Activity of Darunavir against SARS-CoV-2. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.04.03.20052548v1 (2020)."},{"key":"70143_CR20","doi-asserted-by":"crossref","unstructured":"Kuster, G. M. et al. SARS-CoV2: should inhibitors of the renin\u2013angiotensin system be withdrawn in patients with COVID-19? Eur. Heart J. ehaa235 (2020).","DOI":"10.1093\/eurheartj\/ehaa235"},{"key":"70143_CR21","doi-asserted-by":"crossref","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature (2020).","DOI":"10.1038\/s41586-020-2180-5"},{"key":"70143_CR22","unstructured":"Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04356495 (2020)."},{"key":"70143_CR23","doi-asserted-by":"crossref","unstructured":"CDCMMWR. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019\u2014United States, February 12\u2013March 28, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, (2020).","DOI":"10.15585\/mmwr.mm6913e2"},{"key":"70143_CR24","doi-asserted-by":"crossref","unstructured":"Miyara, M. et al. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios (2020).","DOI":"10.32388\/WPP19W"},{"key":"70143_CR25","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan, W. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708\u20131720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"70143_CR26","doi-asserted-by":"publisher","first-page":"R895","DOI":"10.1152\/ajpregu.00099.2018","volume":"315","author":"JM Oakes","year":"2018","unstructured":"Oakes, J. M., Fuchs, R. M., Gardner, J. D., Lazartigues, E. & Yue, X. Nicotine and the renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 315, R895\u2013R906 (2018).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"70143_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41429-019-0204-x","volume":"72","author":"DH Tran","year":"2019","unstructured":"Tran, D. H. et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J. Antibiot. (Tokyo) 72, 759\u2013768 (2019).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"70143_CR28","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1128\/JVI.00203-09","volume":"83","author":"EC Goodwin","year":"2009","unstructured":"Goodwin, E. C., Atwood, W. J. & DiMaio, D. High-throughput cell-based screen for chemicals that inhibit infection by simian virus 40 and human polyomaviruses. J. Virol. 83, 5630\u20135639 (2009).","journal-title":"J. Virol."},{"key":"70143_CR29","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1097\/01.CCM.0000120055.52377.BF","volume":"32","author":"P Dahlem","year":"2004","unstructured":"Dahlem, P., van Aalderen, W. M. C., de Neef, M., Dijkgraaf, M. G. W. & Bos, A. P. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med. 32, 1055\u20131060 (2004).","journal-title":"Crit Care Med."},{"key":"70143_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.antiviral.2017.09.004","volume":"146","author":"N Mumtaz","year":"2017","unstructured":"Mumtaz, N. et al. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. Antiviral Res. 146, 161\u2013163 (2017).","journal-title":"Antiviral Res."},{"key":"70143_CR31","doi-asserted-by":"crossref","unstructured":"Maisonnasse, P. et al. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non- human primates. Preprint at https:\/\/www.researchsquare.com\/article\/rs-27223\/v1 (2020).","DOI":"10.21203\/rs.3.rs-27223\/v1"},{"key":"70143_CR32","doi-asserted-by":"crossref","unstructured":"Weston, S. et al. Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. bioRxiv 2020.03.25.008482 (2020).","DOI":"10.1101\/2020.03.25.008482"},{"key":"70143_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/v10040184","volume":"10","author":"J Haviernik","year":"2018","unstructured":"Haviernik, J. et al. Arbidol (Umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses 10, 184 (2018).","journal-title":"Viruses"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70143-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70143-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70143-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:59:29Z","timestamp":1670320769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70143-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70143"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70143-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.03.023846","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13093"}}